To The Moon

$AstraZeneca PLC(AZN)$’s second-quarter results showed strong commercial execution, particularly in oncology, but the company’s long-term valuation still depends on clinical-trial outcomes that are inherently uncertain.

The company published its results on July 27 for the quarter ended June 30. Total revenue increased 5% at constant exchange rates to $15.38 billion. Core earnings rose 18% to $2.63 per share, exceeding the approximately $2.48 expected by analysts. Oncology revenue grew 15%, while rare-disease revenue increased 8%. Reuters’ July 27 results report provides the figures.

AstraZeneca maintained its 2026 guidance for mid-to-high-single-digit revenue growth and low-double-digit core-EPS growth. It also reaffirmed its ambition to reach $80 billion of annual revenue by 2030.

The bullish thesis is built on diversification within its pharmaceutical portfolio. Strong cancer-drug demand means the company does not rely on a single product, while management expects more than 20 potentially important trial results during the next 18 months. AstraZeneca also increased its estimate of potential peak revenue for respiratory treatment tozorakimab to more than $5 billion.

However, those trials create “binary” risk: a successful outcome can materially increase a drug’s value, while a failed endpoint may eliminate much of its expected revenue. Recent disappointing results involving Wainua and camizestrant illustrate that risk. Loss of US exclusivity for Farxiga also creates pressure for newer medicines to replace maturing products.

AstraZeneca’s US-listed shares traded around $169 in Monday’s premarket session, modestly above Friday’s close near $168.44.

AZN Daily Chart

AZN’s daily chart is attempting to form a short-term base after the sharp gap-down, with price consolidating between roughly $164 and $171 and showing a possible rounded-bottom structure.

The immediate level to watch is $174, which has become the first meaningful resistance after the breakdown; a decisive daily close above this level would improve momentum and could open a recovery toward the lower edge of the unfilled gap near $180, followed by the broader $185–$188 gap zone.

Until $174 is reclaimed, the stock remains vulnerable to another retest of $164–$165, so buying calls immediately would be premature. The cleaner trade would be a 45–75 DTE $175/$185 call debit spread entered only after a confirmed breakout above $174, which provides defined-risk exposure to a partial gap fill while limiting time decay. A close below approximately $164 would invalidate the developing base and suggest that downside pressure remains in control.

The evidence leans moderately bullish because oncology growth, earnings and guidance remain intact. The view would be invalidated by additional major trial failures, weaker oncology growth or evidence that new products cannot offset patent-related revenue losses. This is personal opinion for education and is not financial advice.

@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion

Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.